Company: ZURA
Filing Date: 2025-04-23
Form Type: DEF 14A
Source: 0001104659-25-038042
Chunk: 56

Company: Zura Bio Ltd
Filing Date: 2025-04-23
Form: DEF 14A
Chunk 56
---
 | ​ | ​               | ​ |     84,300 | ​ | ​ | ​ | ​                   | ​ | *      | ​ | ​ |
| Dan Becker(18)                                                                              | ​ | ​ | ​               | ​ |          — | ​ | ​ | ​ | ​                   | ​ | —      | ​ | ​ |
| All current executive officers, directors and director nominees as a group (15 individuals) | ​ | ​ | ​               | ​ | 10,407,705 | ​ | ​ | ​ | ​                   | ​ | 14.23% | ​ | ​ |

33

TABLE OF CONTENTS (*) Represents beneficial ownership of less than 1%. (1) The indicated ownership is based in part on a Schedule 13G filed with the SEC on November 14, 2024 by Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh (collectively, the “Venrock Holders”). Consists of (i) 959,248 Class A ordinary shares and 1,312,029 Class A ordinary shares underlying pre-funded warrants (“PFWs”), which are exercisable at any time or times on or after the date of issuance, held by Venrock Healthcare Capital Partners III, L.P.; (ii) 96,005 Class A ordinary shares and 131,263 Class A ordinary shares underlying PFWs, which are exercisable at any time or times on or after the date of issuance, held by VHCP Co-Investment Holdings III, LLC; and (iii) 3,967,913 Class A ordinary shares and 4,577,950 Class A ordinary shares underlying PFWs, which are exercisable at any time or times on or after the date of issuance, held by Venrock Healthcare Capital Partners EG, L.P. Under the terms of the PFWs, the Company shall not effect the exercise of any portion of the PFWs, and the holder shall not have the right to exercise any portion of such PFWs, if, upon giving effect to such exercise, the aggregate number of Class A ordinary shares beneficially owned by the holder (together with its affiliates and other attribution parties) would exceed 9.99% of the number of Class A ordinary shares outstanding immediately after giving effect to the exercise. All of the